Unlike treatment with EGFR-TKIs and ALK-TKIs, advanced NSCLC patients with high levels of serum CRP, serum LDH, and a poor PS might not be suitable for treatment with nivolumab. This evidence concerns the gene ALK and non-small cell lung carcinoma.